Preclinical studies of a factor X activator and a phase 1 trial for hemophilia patients with inhibitors

• DOI: 10.1016/j.jtha.2023.01.040
• Publication Date: 2023-02-14T21:52:32Z
• Authors: Wei Liu; Feng Xue; Rongfeng Fu; Bingjie Ding; Mengjuan Li; Ting Sun; Yunfei Chen; Xiaofan Liu; Mankai Ju; Xinyue Dai; Quanrui Wu; Zan Zhou; Jiaojiao Yu; Xiaomin Wang; Qing Zhu; Hu Zhou; Renchi Yang; Lei Zhang
• Keywords: Cysteine Endopeptidases; Humans; Hemophilia A; Antibodies; 3. Good health; Neoplasm Proteins

Bleeding episodes in hemophiliacs with inhibitors are difficult to control. Staidson protein-0601 (STSP-0601), a specific factor (F)X activator purified from the venom of Daboia russelii siamensis, has been developed.We aimed to investigate the efficacy and safety of STSP-0601 in preclinical and clinical studies.In vitro and in vivo preclinical studies were performed. A phase 1, first-in-human, multicenter, and open-label trial was conducted. The clinical study was divided into parts A and B. Hemophiliacs with inhibitors were eligible for this study. Patients received a single intravenous injection of STSP-0601 (0.01 U/kg, 0.04 U/kg, 0.08 U/kg, 0.16 U/kg, 0.32 U/kg, or 0.48 U/kg) in part A or a maximum of 6 4-hourly injections (0.16 U/kg) in part B. The primary endpoint for each part was the number of adverse events (AEs) from baseline to 168 hours after administration. This study was registered at clinicaltrials.gov (NCT-04747964 and NCT-05027230).Preclinical studies showed that STSP-0601 could specifically activate FX in a dose-dependent manner. In the clinical study, 16 patients in part A and 7 patients in part B were enrolled. Eight (22.2%) AEs in part A and 18 (75.0%) AEs in part B were reported to be related to STSP-0601. Neither severe AEs nor dose-limiting toxicity events were reported. There were no thromboembolic event. The antidrug antibody of STSP-0601 was not detected.Preclinical and clinical studies showed that STSP-0601 had a good ability to activate FX and had a good safety profile. STSP-0601 could be used as a hemostatic treatment in hemophiliacs with inhibitors.